PsiOxus is committed to develop our pipeline through the establishment of strategic partnerships with leading immuno-oncology companies and academic groups. We are currently seeking strategic immuno-oncology partners for next generation oncolytic virus products from our proprietary T-SIGn platform technology, including:

  • Out-license of PsiOxus novel T-SIGn preclinical products
  • Research collaborations to develop novel virus programs
  • Research collaborations to develop programs using proprietary partner transgene combinations

For more information or inquiries on collaborations and partnerships, please contact

Strategic Collaborations

Back to Top